Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Oct;41(10):2317–2319. doi: 10.1128/aac.41.10.2317

Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections.

P Ringwald 1, J Bickii 1, A Same-Ekobo 1, L K Basco 1
PMCID: PMC164120  PMID: 9333075

Abstract

The clinical efficacy of oral pyronaridine was assessed in 22 symptomatic Cameroonian patients infected with Plasmodium ovale or Plasmodium malariae. All patients were cured on or before day 4. In vitro drug assays confirmed the sensitivity of P. ovale and P. malariae isolates to chloroquine and pyronaridine.

Full Text

The Full Text of this article is available as a PDF (121.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baird J. K., Basri H., Subianto B., Fryauff D. J., McElroy P. D., Leksana B., Richie T. L., Masbar S., Wignall F. S., Hoffman S. L. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis. 1995 Jun;171(6):1678–1682. doi: 10.1093/infdis/171.6.1678. [DOI] [PubMed] [Google Scholar]
  2. Basco L. K., Le Bras J. Short-term in vitro culture of Plasmodium vivax and P. ovale for drug-susceptibility testing. Parasitol Res. 1994;80(3):262–264. doi: 10.1007/BF00932686. [DOI] [PubMed] [Google Scholar]
  3. Chang C., Lin-Hua T., Jantanavivat C. Studies on a new antimalarial compound: pyronaridine. Trans R Soc Trop Med Hyg. 1992 Jan-Feb;86(1):7–10. doi: 10.1016/0035-9203(92)90414-8. [DOI] [PubMed] [Google Scholar]
  4. Fu S., Xiao S. H. Pyronaridine: A new antimalarial drug. Parasitol Today. 1991 Nov;7(11):310–313. doi: 10.1016/0169-4758(91)90267-r. [DOI] [PubMed] [Google Scholar]
  5. Looareesuwan S., Kyle D. E., Viravan C., Vanijanonta S., Wilairatana P., Wernsdorfer W. H. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am J Trop Med Hyg. 1996 Feb;54(2):205–209. doi: 10.4269/ajtmh.1996.54.205. [DOI] [PubMed] [Google Scholar]
  6. Mount D. L., Nahlen B. L., Patchen L. C., Churchill F. C. Adaptations of the Saker-Solomons test: simple, reliable colorimetric field assays for chloroquine and its metabolites in urine. Bull World Health Organ. 1989;67(3):295–300. [PMC free article] [PubMed] [Google Scholar]
  7. Olliaro P. L., Trigg P. I. Status of antimalarial drugs under development. Bull World Health Organ. 1995;73(5):565–571. [PMC free article] [PubMed] [Google Scholar]
  8. Ringwald P., Bickii J., Basco L. K. In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg. 1996 Sep;55(3):254–258. doi: 10.4269/ajtmh.1996.55.254. [DOI] [PubMed] [Google Scholar]
  9. Ringwald P., Bickii J., Basco L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet. 1996 Jan 6;347(8993):24–28. doi: 10.1016/s0140-6736(96)91558-5. [DOI] [PubMed] [Google Scholar]
  10. Tan-ariya P., Pasuralertsakul S. First report of in vitro susceptibility of Plasmodium malariae Thai isolates to chloroquine. Southeast Asian J Trop Med Public Health. 1994 Dec;25(4):784–787. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES